C-reactive protein levels in the early stage of COVID-19

By W. Ling. Médecine et maladies infectieuses, 2020

626 citations recorded by the source corpus.

Background COVID-19 is a new infectious disease, for which there is currently no treatment. It is therefore necessary to explore biomarkers to determine the extent of lung lesions and disease severity. Objective We aimed to assess the usefulness of CRP levels in the early stage of COVID-19 and to correlate them with lung lesions and severe presentation. Methods Confirmed cases of COVID-19 were selected at the Fever Unit in two regions of Guizhou, China. On admission CRP levels were collected, and the diameter of the largest lung lesion was measured in the most severe lung lesion by lung CT scan. Differences in the diameter and CRP levels were compared in the following groups of patients: mild group, moderate group, severe group, and critical group. Result CRP levels and the diameter of the largest lung lesion in the moderate group were higher than those in the mild group (Mann-Whitney test = −2.647, −2.171, P ˂ 0.05), those in the severe group were higher than those in the moderate group (Mann-Whitney test = 0.693, −2.177, P ˂ 0.05), and those in the critical group were higher than those in the severe group (Mann-Whitney test = −0.068, −1.549, P ˂ 0.05). The difference was statistically significant. CRP levels were positively correlated with the diameter of lung lesion and severe presentation (correlation coefficient = 0.873, 0.734, P ˂ 0.001). Conclusion In the early stage of COVID-19 CRP levels were positively correlated with lung lesions and could reflect disease severity.

Subfields: Epidemiology, Infectious Diseases, Oncology

View Paper: https://www.semanticscholar.org/paper/0f9cc07146d624b40f077158e3216854a272ba77

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

W. Garcia-Beltran
Evan C. Lam
Adam D Nitido
B. Hauser
J. Feldman
A. Balazs
K. Clayton
M. Astudillo

Citations in the corpus

COVID-19 neutralizing antibodies predict disease severity and survival (2020, positive): “…levels of C-reactive protein (Figure 1B), ferritin (Figure S1A), D-dimer (Figure S1B), lactate dehydrogenase (Figure S1C), and interleukin (IL)-6 (Figure 1C), as well as lymphopenia (Figure 1D), as has been previously shown (Wang, 2020; Zhou et al., 2020b; Wynants et al., 2020; Chen et al., 2020b).”